Karo Bio is a pharmaceutical company that develops innovative drugs for key medical needs.
Our core competence lies within nuclear receptors, which control biological processes at the genetic level. Through them the body’s own control systems for important functions can be switched on or off.
Karo Bio’s vision is to become a pharmaceutical company with sustainable profitability, commercial products and a competitive project portfolio that combines collaborative projects with its own development projects.
Karo Bio focuses on nuclear receptors as target proteins for the development of new drugs. Our development projects are within the indications neuropsychiatry, inflammation, cancer and women’s health.
CEO Per Bengtsson will present the report in an audiocast. The presentation will be held in Swedish.
Karo Bio’s research foundation has decided to extend the application dead-line 2012 to 1 May.
